Neurenati Therapeutics Closes Second Seed Financing of $1.7M


Neurenati Therapeutics, a Montreal, Québec, Canada-based biotech company dedicated to developing therapies for rare diseases, raised $1.38M in funding.

Quebec Government made the investment via its Impulsion PME program. Angels participated in the second close.

The company intends to use the funds to effectively advance NEU-001 toward clinical trials.

Led by CEO and President Maxime Ranger, Neurenati Therapeutics is a biotech company dedicated to developing therapies for rare diseases. The first technology targets Hirschsprung disease (HSCR), a life-threatening gastrointestinal (GI) birth defect characterized by the lack of nerves in parts of the lower GI tract.

NEU-001 is a proposed first-in-class therapy to treat Hirschsprung’s disease, a rare gastrointestinal disease affecting approximately 1,300 newborns in North America each year.

Neurenati still targets the end of 2025 to file a clinical trial application in Canada and the United States. Moreover, the company is always looking for other technologies in the field of rare diseases, especially in pediatrics.